NCT06249165 VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT06112327 Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease Status ENROLLING_BY_INVITATION Phase N/A
NCT06048588 YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis Status COMPLETED Phase PHASE1/PHASE2
NCT05976893 Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer Status NOT_YET_RECRUITING Phase PHASE4
NCT05974345 In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease Status COMPLETED Phase N/A
NCT05792787 Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases Status COMPLETED Phase N/A
NCT05765370 LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD) Status RECRUITING Phase NA
NCT05761444 Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients Status COMPLETED Phase PHASE4
NCT05749874 Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT05724615 Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids) Status COMPLETED Phase NA
NCT05705804 Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial Status UNKNOWN Phase NA
NCT05659888 Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE Status COMPLETED Phase N/A
NCT05639218 Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05581303 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05485961 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Status RECRUITING Phase PHASE2/PHASE3